Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
Cell Therapy News
Cell Therapy News is an online resource dedicated to sharing the latest cell therapy, gene therapy, and regenerative medicine research.
Preferential Tumor Targeting of HER2 by iPSC-Derived CAR T Cells Engineered to Overcome Multiple Barriers to Solid Tumor Efficacy
[Cell Stem Cell] Investigators described an iPSC-derived CAR T cell that combines a human epidermal growth factor receptor 2 (HER2)-targeting CAR with multiplex editing designed to address and overcome obstacles to maximize efficacy in solid tumor indications.
Targeting CD117 on Hematopoietic Stem and Progenitor Cells Impairs CAR T Cell Activity
[Molecular Therapy] Scientists developed human and mouse CART117 to evaluate the safety and feasibility of targeting CD117 in preclinical mouse models. Human CART117 had potent anti-tumor activity while also mediating significant hematopoietic toxicity in a humanized mouse model.
Senescence and inflammation are unintended adverse consequences of CRISPR-Cas9/AAV6-mediated gene editing in hematopoietic stem cells
[Cell Reports Medicine] Researchers uncovered a durable senescence-like response in genetically engineered hematopoietic stem and progenitor cells triggered by p53 and interleukin-1/nuclear factor κB activation, which restricts graft size and clonal diversity in long-term transplantation assays.
Efficient and Multiplexed Somatic Genome Editing with Cas12a Mice
[Nature Biomedical Engineering] Investigators generated transgenic mice with Cre-regulated and constitutive expression of enhanced Acidaminococcus sp. Cas12a, which robustly generates compound genotypes, including diverse cancers driven by inactivation of trios of tumour suppressor genes or an oncogenic translocation.
Intracerebroventricular Bivalent CAR T Cells Targeting EGFR and IL-13Rα2 in Recurrent Glioblastoma: A Phase I Trial
[Nature Medicine] Researchers reported the dose escalation and exploration phases of a Phase I trial investigating intracerebroventricular delivery of bivalent CAR T cells targeting epidermal growth factor receptor (EGFR) epitope 806 and interleukin-13 receptor alpha 2 (IL-13Rα2), or CART-EGFR-IL13Rα2 cells, in patients with EGFR-amplified recurrent glioblastoma.
Secretion of a VEGF-Blocking scFv Enhances CAR T-Cell Potency
[Cancer Immunology Research] Investigators showed that CAR T cells from patients treated with FDA-approved CAR T-cell products express members of the VEGF signaling pathway and this expression is correlated with patient non-response.
Anti-Viral CD8 Central Memory Veto Cells As a New Platform for CAR T Cell Therapy
[Stem Cells Translational Medicine] Human anti-viral CD8 central memory veto T cells generated from CMV and EBV-positive donors were evaluated in a clinical trial at MD Anderson Cancer Centre.
Advances in Viral Vector-Based Delivery Systems for Gene Therapy: A Comprehensive Review
[3 Biotech] Investigators explore recent advancements in viral vector platforms, focusing on intracellular trafficking, transgene expression, and strategies to optimize vector design.
STEMCELL Technologies Announces Acquisition of Cellular Highways
[STEMCELL Technologies] STEMCELL Technologies announced the acquisition of Cellular Highways Ltd. Cellular Highways specializes in advanced cell sorting technologies with applications in cell and gene therapy, drug discovery, and general cell research, especially where cells are fragile.
ImmunityBio Receives FDA Expanded Access Authorization for Landmark Treatment of Lymphopenia with ANKTIVA®, the Cancer BioShield™ Platform, in Patients with Solid Tumors
[ImmunityBio, Inc.] ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced that the U.S. Food and Drug Administration (FDA) has granted Expanded Access authorization for the use of its Cancer BioShield™ platform, anchored by ANKTIVA® (nogapendekin alfa inbakicept-pmln), to treat lymphopenia in adult patients with refractory or relapsed solid tumors independent of tumor type who have progressed after first-line standard-of-care treatment, chemotherapy, radiation, or immunotherapy.
In Vivo Hemopoietic Stem Cell Gene Therapy Enabled by Postnatal Trafficking
[Nature] Scientists demonstrated that in vivo gene delivery to hematopoietic stem and progenitor cells after systemic lentiviral administration is enabled by the substantial trafficking of these cells from the liver to the bone marrow in newborn mice.
Remodeling Hypoxic TNBC Microenvironment Restores Antitumor Efficacy of Vγ9Vδ2 T Cell Therapy
[British Journal of Cancer] Data from TCGA, publicly available scRNA-seq datasets, and a series of experiments including flow cytometry, atomic force microscopy, confocal laser scanning microscopy, mouse model and others were applied to examine the functional heterogeneity of γδ T cells in TNBC, non-TNBC, and healthy individuals.
Published since 2002, Cell Therapy News is our longest running online publication. Our editorial team curates the top publications, reviews, and news on in vivo gene therapy, cell therapy, and immunotherapy research. With over 15,000 subscribers and followers across our website, email newsletter, and Twitter feed, we are proud to facilitate the communication of cutting-edge cell therapy innovations.
